Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:35 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Cambridge Brain Mets Trial 1
NCT02768337 · Cambridge University Hospitals NHS Foundation Trust · PHASE1/PHASE2 · terminated · last registry update 2024-01-31 · Non-small cell lung cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Slow recruitment” | – | Registry record, Cambridge University Hospitals NHS Foundation Trust |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against EGFR in non-small cell lung cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-01-28Results posted on the registry: MedSIR, Osimertinib (NCT02841579)
- 2025-01-14Results posted on the registry: ETOP IBCSG Partners Foundation, Osimertinib + Bevacizumab (NCT03133546)
- 2025-01-06Phase 3 first posted: Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd., FHND9041 + Afatinib (NCT06759857)
- 2024-12-16Phase 3 first posted: Shanghai JMT-Bio Inc., JMT101 + Osimertinib (NCT06735391)
- 2024-12-10Also stopped (withdrawn): Sun Yat-sen University, Nimotuzumab + Gemcitabine (NCT02428764)
- 2024-12-10Also stopped (withdrawn): Sun Yat-sen University, Aumolertinib (NCT06227897)
- 2024-11-01Phase 3 first posted: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., SKB264 + Osimertinib (NCT06670196)
- 2024-10-09Results posted on the registry: Janssen Research & Development, LLC, Amivantamab + Osimertinib (NCT04487080)
- 2024-09-24Results posted on the registry: AstraZeneca, Osimertinib + Savolitinib + Savolitinib + Placebo (NCT04606771)
- 2024-08-06Results posted on the registry: AstraZeneca, Osimertinib + Pemetrexed/Carboplatin (NCT04035486)
- 2024-07-03Phase 3 first posted: Region Skane, Afatinib/Dacomitinib + Osimertinib (NCT06486142)
- 2024-06-04Results posted on the registry: EMD Serono Research & Development Institute, Inc., Tepotinib + Osimertinib (NCT03940703)
- 2024-05-16Phase 3 first posted: AstraZeneca, Dato-DXd + Osimertinib (NCT06417814)
- 2024-05-16Phase 3 first posted: Hansoh BioMedical R&D Company, HS-20117 + Aumolertinib (NCT06417008)
- 2024-04-12Results posted on the registry: Millennium Pharmaceuticals, Inc., Midazolam + TAK-788 (NCT04051827)
- 2024-04-05Phase 3 first posted: AstraZeneca, Osimertinib + Datopotamab Deruxtecan (NCT06350097)
- 2024-03-22Results posted on the registry: Yuhan Corporation, Lazertinib 240 mg/160 mg + Gefitinib 250 mg (NCT04248829)
- 2024-02-28Results posted on the registry: Janssen Research & Development, LLC, Lazertinib (NCT04075396)
- 2024-01-18Results posted on the registry: University of California, San Francisco, Osimertinib (NCT03433469)
- 2023-11-21Results posted on the registry: National Cancer Institute (NCI), Alectinib + Brigatinib (NCT03737994)
- 2023-10-03Results posted on the registry: Takeda, Mobocertinib (NCT03807778)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision